Evaluation of molecular and imaging markers for the optimization of diagnostic strategies in the context of individualized therapy of non-small cell lung cancer

Documenti analoghi

• Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC)
  di: Schmid-Bindert, Gerald
  Pubblicazione: (2013)
• A randomized phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II non-small-cell lung cancer
  di: Schmid-Bindert, Gerald
  Pubblicazione: (2015)
• Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: a double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)
  di: O'Brien, Mary, et al.
  Pubblicazione: (2015)
• A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)
  di: Ramalingam, Suresh, et al.
  Pubblicazione: (2015)
• Targeted therapy for patients with BRAF-mutant lung cancer: results from the European EURAF Cohort
  di: Gautschi, Oliver, et al.
  Pubblicazione: (2015)